Global market access and pricing specialists

A strong market access strategy can result in higher levels of investment, higher exit values and increased launch success*. So, whether your goal is fundraising, partnering or commercialisation, our team of former pharmaceutical executives and global network of in-market experts are here to help.

Global expertise for
locally relevant advice

Our team of global experts can help you to build your market access and pricing strategy, to maximize your commercial potential. As your strategic partner, we will help you to manage expectations and achieve the best-possible outcomes.

contact fingerpost consulting
contact us

How we can help youThere are a variety of ways you can pull on the specialist global knowledge of the FingerPost network.

Commercial Viability for pre-clinical assets

By applying a commercial lens to support target selection prior to clinical development, we advise on the patient populations that are most likely to drive interest for investors and partners.

We also review pitch deck material and advise on gaps that could be strengthened.

Economic Opportunity for assets in Phase 1-3

Robust pricing analysis and economic modelling is required to demonstrate the revenue potential of assets to investors / acquirers, while identifying the optimal value-based pricing strategy.

This work helps establish clear price points that maximise value, while ensuring market access: a critical consideration for valuation.

Clinical trial design for assets preparing for Phase 2b or 3

For successful partnering and commercialization, it’s important to ensure clinical trial design captures the data required for reimbursement evaluations.

Our Advisors will identify areas of the design that may need adjusting, without compromising regulatory requirements, to support optimal value demonstration to Payers.

Joint Clinical Assessment (JCA) services

JCA now means that certain assets (oncology, ATMPs, and soon to include orphan drugs) need to submit for European HTA at the same time as the regulatory dossiers in Europe.

This requires preparation within 1-2 years of the regulatory filing date, regardless of partnering objectives. Our team has developed a targeted service offering for smaller biopharma companies who are looking for an exit or planning to launch with limited internal market access resources. 

Buy-side evaluations

Valuations of assets can be complicated and are often underpinned by the price and reimbursement opportunity.

We will run a parallel analysis and / or validate key assumptions for assets under consideration on the buy-side to provide an external perspective on the opportunities and challenges likely to face an asset at launch.

Launch Support

Our experienced Market Access team works closely with our local affiliate teams to help prepare for and implement the launch of new assets across Europe, Canada and Australia.

This is particularly suited to companies with limited internal market access resources or those with limited experience of launching innovative treatments.

What does Market Access involve?

Market Access is complicated. Many therapies struggle commercially despite receiving regulatory approval, with 33-66% of launches failing to meet sales expectations.

We’ve created this short Market Access explainer, to give an overview of what it is and why it’s important.

What’s the difference between Patient Access and Market Access?

Patient Access is all about ensuring that healthcare innovations ultimately reach the patients who need them e.g., drugs / therapeutics / medtech devices

We can view Patient Access as the overarching, inclusive mission. It includes every step in the pathway, from regulatory approval, through to patient outcomes – this is what we are all striving toward.

Market Access can be thought of as a set of capabilities. To achieve Patient Access, we need to plan for Market Access, and work seamlessly with many other functions.

How it all fits together

Patient Access
Market Access Strategy
Regulatory Strategy
Reimbursement / Pricing Strategy
Health Technology Assessment
Regulatory / Payer Outcomes
Evidence Generation
Clinical / Patient / Payer Validation
Value Story

Why is Market Access important?

Clinical success isn’t the same as commercial success. Market Access can be the difference between a great healthcare innovation successfully launching or failing. Getting the right advice on your strategy can save time, money and pain.

A good strategic plan helps to:

Ensure you have the right evidence
Optimise your price potential
Secure positive HTA outcomes
Build the case for investment and partnering
Ensure reimbursement success
Ultimately, you need the right Market Access strategy to unlock patient access to new treatments.

When should you think about Patient and Market Access?

You should be thinking about Patient and Market Access from the very beginning, to optimise your chances of success.
Market Access is being much more widely talked about (sometimes synonymously with Patient Access). This means that investors/partners now expect you to confidently address questions on this at an earlier stage. We recommend starting this work at pre-clinical stage / Phase 1.

Get in Touch

We'd love to discuss your challenges and any potential need for support. Please fill out the form or send an email and we will get back to you as soon as possible.

goldman sachs
bhbia